TNFSF13B and systemic lupus erythematosus: Anti-BAFF. Since its initial approval by the U.S. Food and Drug administration (FDA) in March of 2011, belimumab has consistently demonstrated an overall reassuring safety profile in comparison to standard of care (SOC) therapy in both adult and pediatric SLE patients (Table 2).